The layoffs will only affect employees at the Allston Landing plant, which is a biomanufacturing site.
“We must be flexible in our operations to remain competitive in a dynamic and challenging healthcare environment,” said Ashleigh Koss, spokeswoman for Sanofi SA, the French parent company, according to the Boston Globe.
Sanofi Genzyme is a rare disease division of Sanofi SA. It employs about 5,000 employees in Massachusetts.
More articles on supply chain:
Celgene Executive Chairman Bob Hugin abruptly steps down: 5 things to know
As flu rages throughout Florida, Tamiflu supplies run low
Pfizer’s opioid-filled syringes hit another manufacturing snag: 6 things to know
